Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

被引：0
|
作者：
Neuen, B. L. [1 ]
Oshima, M. [1 ]
Perkovic, V. [2 ]
Arnott, C. [1 ]
Bakris, G. [3 ]
Cannon, C. P. [4 ]
Charytan, D. M. [5 ]
Jardine, M. [6 ]
Levin, A. [7 ]
Neal, B. [1 ]
Pollock, C. [6 ]
Wheeler, D. C. [8 ]
Mahaffey, K. W. [9 ]
Heerspink, H. J. L. [10 ]
机构：
[1] George Inst Global Hlth, Sydney, NSW, Australia
[2] Univ New South Wales Sydney, Sydney, NSW, Australia
[3] Univ Chicago Med, Chicago, IL USA
[4] Harvard Med Sch, Boston, MA 02115 USA
[5] NYU, Langone Med Ctr, New York, NY USA
[6] Univ Sydney, Sydney, NSW, Australia
[7] Univ British Columbia, Vancouver, BC, Canada
[8] UCL, London, England
[9] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[10] Univ Med Ctr Groningen, Groningen, Netherlands
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2647 / 2647
页数：1
相关论文
共 50 条
  • [1] Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
    Neuen, Brendon L.
    Oshima, Megumi
    Perkovic, Vlado
    Agarwal, Rajiv
    Arnott, Clare
    Bakris, George
    Cannon, Christopher P.
    Charytan, David M.
    Edwards, Robert
    Gorriz, Jose L.
    Jardine, Meg J.
    Levin, Adeera
    Neal, Bruce
    De Nicola, Luca
    Pollock, Carol
    Rosenthal, Norman
    Wheeler, David C.
    Mahaffey, Kenneth W.
    Heerspink, Hiddo J. L.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (48) : 4891 - +
  • [2] CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL
    Neuen, Brendon
    Fletcher, Robert
    Arnott, Clare
    Vadagunathan, Muthiah
    Perkovic, Vlado
    Jardine, Meg
    Neal, Bruce
    Mahaffey, Kenneth
    Heerspink, Hiddo
    Pollock, Carol
    [J]. NEPHROLOGY, 2022, 27 : 15 - 15
  • [3] Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease Insights From the CREDENCE Trial
    Ye, Nan
    Jardine, Meg J.
    Oshima, Megumi
    Hockham, Carinna
    Heerspink, Hiddo J. L.
    Agarwal, Rajiv
    Bakris, George
    Schutte, Aletta E.
    Arnott, Clare
    Chang, Tara I.
    Gorriz, Jose L.
    Cannon, Christopher P.
    Charytan, David M.
    de Zeeuw, Dick
    Levin, Adeera
    Mahaffey, Kenneth W.
    Neal, Bruce
    Pollock, Carol
    Wheeler, David C.
    Luca Di Tanna, Gian
    Cheng, Hong
    Perkovic, Vlado
    Neuen, Brendon L.
    [J]. CIRCULATION, 2021, 143 (18) : 1735 - 1749
  • [4] Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
    Natale, Patrizia
    Palmer, Suetonia C.
    Ruospo, Marinella
    Saglimbene, Valeria M.
    Strippoli, Giovanni F. M.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (06):
  • [5] Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
    Oshima, Megumi
    Neuen, Brendon L.
    Jardine, Meg J.
    Bakris, George
    Edwards, Robert
    Levin, Adeera
    Mahaffey, Kenneth W.
    Neal, Bruce
    Pollock, Carol
    Rosenthal, Norman
    Wada, Takashi
    Wheeler, David C.
    Perkovic, Vlado
    Heerspink, Hiddo J. L.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11): : 903 - 914
  • [6] Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial
    Koshino, Akihiko
    Oshima, Megumi
    Arnott, Clare
    Fletcher, Robert A.
    Bakris, George L.
    Jardine, Meg
    Mahaffey, Kenneth W.
    Perkovic, Vlado
    Pollock, Carol
    Heerspink, Hiddo J. L.
    Neuen, Brendon L.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (05): : 1413 - 1418
  • [7] EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR AND KIDNEY EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT PERIPHERAL VASCULAR DISEASE: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL
    Levin, Adeera
    Poirier, Paul
    Seufert, Jochen
    Slee, April
    Rapattoni, Wally
    Ang, Fernando
    Wheeler, David
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I892 - I893
  • [8] Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
    Sharma, Abhinav
    Razaghizad, Amir
    Joury, Abdulaziz
    Levin, Adeera
    Bajaj, Harpreet S.
    Mancini, G. B. John
    Wong, Norman C.
    Slee, April
    Ang, Fernando G.
    Rapattoni, Wally
    Neuen, Brendon L.
    Arnott, Clare
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (03):
  • [9] Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
    Yi, Tae Won
    Wong, Michelle M. Y.
    Neuen, Brendon L. L.
    Arnott, Clare
    Poirier, Paul
    Seufert, Jochen
    Slee, April
    Rapattoni, Wally
    Ang, Fernando G. G.
    Wheeler, David C. C.
    Mahaffey, Kenneth W. W.
    Perkovic, Vlado
    Levin, Adeera
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 2043 - 2047
  • [10] Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
    Januzzi, James L.
    Mohebi, Reza
    Liu, Yuxi
    Sattar, Naveed
    Heerspink, Hiddo J. L.
    Tefera, Eshetu
    Vaduganathan, Muthiah
    Butler, Javed
    Yavin, Yshai
    Li, Jingwei
    Pollock, Carol A.
    Perkovic, Vlado
    Neal, Bruce
    Hansen, Michael K.
    [J]. CIRCULATION, 2023, 148 (08) : 651 - 660
12345